Equalizing access to innovative treatments across EMEA & CIS
About Us
Since 2013, Inpharmus has been the leading commercialization partner connecting innovator biopharma with high-potential, underserved markets across EMEA & CIS (Europe, the Middle East, Africa and the Commonwealth of Independent States), together covering 520 million people.
We accelerate patient access to life-changing oncology, hematology and rare disease treatments, address a fundamental market gap by connecting innovation with patients in need, and make our Region more accessible, more navigable, and better served.
We provide to our partners a reliable, evidence driven expertise across all stakeholders, ensuring that Our Partners’ products are managed with the highest standards of safety, compliance, and operational precision.
Explore Markets
Inpharmus has an established presence in each of the territories shown on this interactive map.
Click on a region to learn more about our regional operations and the local market opportunities we can help you access.
Discover Regional Footprint ›What does Inpharmus do?
Inpharmus is a biopharmaceutical commercialization partner. Since 2013 it has connected innovator biopharma companies with high-potential, underserved markets across EMEA & CIS, accelerating patient access to oncology, hematology and rare disease treatments.
Which regions does Inpharmus operate in?
Inpharmus operates across EMEA & CIS (Europe, the Middle East, Africa and the Commonwealth of Independent States). This region is home to 520 million people, and Inpharmus organizes it into three regions:
- CEE: Europe, with Switzerland as the main hub
- MENAT (Middle East, North Africa & Türkiye): Türkiye, Saudi Arabia, the United Arab Emirates, Kuwait, Bahrain, Oman, Qatar, Iraq and Algeria
- CIS: Russia, Kazakhstan and Uzbekistan
Which therapeutic areas does Inpharmus focus on?
Oncology, hematology and rare diseases. In rare diseases, the focus is on neurological, metabolic, autoinflammatory and immune-mediated disorders, each affecting fewer than 1 in 50,000 people.
How does Inpharmus support its biopharma partners?
Inpharmus manages partners’ products across all stakeholders with the highest standards of safety, compliance and operational precision.
Where are Inpharmus’ offices?
- CEE – Europe Regional Office / Main Hub: Inpharmus AG, Zählerweg 12, 6300 Zug, Switzerland
- MENAT – Türkiye Regional Office: Kanyon Ofis Bloğu, Büyükdere Cd. No: 185 Kat: 14, 34394 Levent-Şişli, Istanbul, Türkiye
- MENAT – Dubai Regional Office: Dubai Science Park, North Tower, Floor 11, Office 1104, Al Barsha South, Dubai, United Arab Emirates
- CIS – Russia Regional Office: 4th Lesnoy Lane 13, Tverskoy municipal district, 125196 Moscow, Russian Federation
Which companies does Inpharmus partner with?
Servier, Sobi, Chiesi, Pharming, SERB Pharmaceuticals, Y-mAbs Therapeutics, Leadiant Biosciences, Immedica Pharma, Fennec Pharmaceuticals and PTC Therapeutics.
How can a biopharma company partner with Inpharmus?
Contact the business development team at partnership@inpharmus.com, or use the form on the Contact page.
How can healthcare professionals request medical information?
Email medinfo@inpharmus.com.
How can I report a product quality complaint?
Email info@inpharmus.com.
Who is the information on this website intended for?
Medical content on this website is intended exclusively for physicians and pharmacists, for informational and educational purposes. It does not replace medical advice.
How can I apply for a job at Inpharmus?
Submit your application through the form on the Careers page.
